Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951651 · ClinicalTrials.gov registry record · Phase 4
Effect of Exenatide on Liver and Heart Fat and Inflammation
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT01951651: Completed Phase 4 study, sponsored by Baylor College of Medicine.
NCT01951651 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01951651, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of exenatide on liver and heart (myocardial) fat and inflammation.
Primary Outcome
Myocardial fat content following intervention as measured by magnetic resonance imaging and spectroscopy (MRS) in patients with type 2 diabetes.
Interventions
- DRUG Exenatide
- DRUG Glipizide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
What the finished NCT01951651 record still lists
NCT01951651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Exenatide is the first listed.
NCT01951651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01951651 about?
NCT01951651 is a clinical study titled "Effect of Exenatide on Liver and Heart Fat and Inflammation". The purpose of this study is to examine the effect of exenatide on liver and heart (myocardial) fat and inflammation.
What is the current status of trial NCT01951651?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2010-04. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01951651?
The interventions under investigation include: Exenatide (DRUG), Glipizide (DRUG).
Who is sponsoring clinical trial NCT01951651?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01951651's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia